Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.

De novo expression of TNF, IFN gamma, IL-3, IL-4, and IL-6 genes was initiated rapidly by treatment of mice with anti-CD3. A specific feature of this reaction was that TNF was derived exclusively from T cells. TNF was produced both as a mature soluble trimeric protein and as a 26-kD anti-TNF-reactive protein compatible with membrane-anchored TNF. Pretreatment with anti-TNF did not affect anti-CD3-triggered TNF mRNA expression in T cells. In contrast, in vivo and in vitro anti-TNF treatment upregulated anti-CD3-induced IFN gamma mRNA expression and inhibited IL-4 mRNA expression. These latter effects were not dependent on TNF neutralization: pretreatment with soluble recombinant 55-kD TNF receptor (TBPI) as an alternative TNF-neutralizing agent did not modify the anti-CD3-induced cytokine profile. These results suggest that a direct interaction between anti-TNF and T cell membrane-anchored TNF could account for the observed modulation of cytokine gene expression. The increased expression of INF gamma mRNA observed in anti-TNF-treated animals correlated with a decrease in IL-3 and IL-6 mRNA expression. Conversely, IFN gamma blockade by a neutralizing anti-IFN gamma mAb led to a substantial increase in both IL-3 and IL-6 gene expression induced by anti-CD3. Taken together, these results strongly argue for the existence, in the anti-CD3-induced cytokine cascade, of IFN gamma-dependent regulation of IL-3 production, which in turn modulates IL-6 production.

[1]  W. Fiers,et al.  Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma , 1992, The Journal of experimental medicine.

[2]  C. Perez,et al.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF , 1988, Cell.

[3]  J. Bluestone,et al.  Identification of a monoclonal antibody specific for a murine T3 polypeptide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Fischer,et al.  CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM , 1993, Nature.

[5]  T. Gajewski,et al.  Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. , 1990, Journal of immunology.

[6]  A. A. Brian,et al.  Stimulation of B-cell proliferation by membrane-associated molecules from activated T cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Fernandez-Botran,et al.  Cross-linking of interleukin 4 to surface molecules on murine T and B lymphocytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Vandenabeele,et al.  Hypothermia and hypoglycemia induced by anti‐CD3 monoclonal antibody in mice: Role of tumor necrosis factor , 1990, European journal of immunology.

[9]  J. Bluestone,et al.  Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. , 1989, Journal of immunology.

[10]  M. Jourdan,et al.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.

[11]  I. Stamenkovic,et al.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐stimulatory activity. , 1992, The EMBO journal.

[12]  T. Gajewski,et al.  Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. , 1988, Journal of immunology.

[13]  J. Bajorath,et al.  The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome , 1993, Cell.

[14]  J. Bluestone,et al.  Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. , 1990, Transplantation.

[15]  K. Ozato,et al.  MONOCLONAL ANTIBODIES TO MOUSE MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGENS: IV. A SERIES OF HYBRIDOMA CLONES PRODUCING ANTI‐H-2d ANTIBODIES AND AN EXAMINATION OF EXPRESSION OF H‐2d ANTIGENS ON THE SURFACE OF THESE CELLS , 1982, Transplantation.

[16]  T. Mustelin,et al.  Molecular events mediating T cell activation. , 1990, Advances in immunology.

[17]  R. Smith,et al.  The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.

[18]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[19]  L. Birnbaumer,et al.  Receptor-to-effector signaling through G proteins: Roles for βγ dimers as well as α subunits , 1992, Cell.

[20]  K. Tracey,et al.  Cachectin/tumor necrosis factor and other cytokines in infectious disease. , 1989, Current opinion in immunology.

[21]  J. Larrick,et al.  Tumor necrosis factor production by human sarcoid alveolar macrophages. , 1986, The American journal of pathology.

[22]  P. Vassalli,et al.  Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Mages,et al.  Cloning of TRAP, a ligand for CD40 on human T cells , 1992, European journal of immunology.

[24]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[25]  C. Thompson,et al.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. , 1989, Science.

[26]  T. Decker,et al.  Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor. , 1989, Journal of immunology.

[27]  D. Remick,et al.  Immunohistochemical demonstration of cytoplasmic and membrane-associated tumor necrosis factor in murine macrophages. , 1988, The American journal of pathology.

[28]  W. Paul,et al.  Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1 , 1985, Nature.

[29]  D. Melton,et al.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. , 1984, Nucleic acids research.

[30]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[31]  W. N. Burnette,et al.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. , 1981, Analytical biochemistry.

[32]  J. Lumley,et al.  Monoclonal antibody to TN F in severe septic shock , 1990, The Lancet.

[33]  C. Dinarello.  The biology of interleukin-1. , 1992, Chemical immunology.

[34]  R. Schreiber,et al.  Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. , 1989, Journal of immunology.

[35]  G. Forni,et al.  Distribution of interferon‐γ receptor in human tissues , 1992 .

[36]  C. Ferran,et al.  Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites. , 1991, Transplantation.

[37]  F. Finkelman,et al.  Anti-CD3 antibody induces rapid expression of cytokine genes in vivo. , 1990, Journal of immunology.

[38]  A. Bruskin,et al.  Localization of a family of MRNAS in a single cell type and its precursors in sea urchin embryos. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[39]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[40]  V. Kindler,et al.  The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection , 1989, Cell.

[41]  J. Renauld,et al.  cDNA cloning of murine interleukin‐HP1: homology with human interleukin 6 , 1988, European journal of immunology.

[42]  V. Kindler,et al.  Prevention of experimental cerebral malaria by anticytokine antibodies. Interleukin 3 and granulocyte macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation , 1988, The Journal of experimental medicine.

[43]  C. Y. Wang,et al.  Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody , 1988, The Journal of experimental medicine.

[44]  N. Young,et al.  Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Trinchieri,et al.  Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes , 1987, The Journal of experimental medicine.

[46]  J. Bluestone,et al.  Inter‐mouse strain differences in the in vivo anti‐CD3 induced cytokine release , 1991, Clinical and experimental immunology.

[47]  T. Maniatis,et al.  Identification of two distinct regulatory regions adjacent to the human β-interferon gene , 1983, Cell.

[48]  K. Herold,et al.  Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways. , 1987, Journal of immunology.

[49]  W. Fiers,et al.  Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma , 1989, The Journal of experimental medicine.

[50]  R. Swoboda,et al.  Regulation of lymphokine expression in T cell activation. I. Rapid loss of interleukin‐specific RNA after removal of the stimulating signal , 1991, European journal of immunology.

[51]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Schreiber,et al.  Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. , 1985, Journal of immunology.

[53]  K. Brorson,et al.  Transcriptional regulation of cytokine genes in nontransformed T cells. Apparent constitutive signals in run-on assays can be caused by repeat sequences. , 1991, Journal of immunology.

[54]  A. Nairn,et al.  Protein kinases 1988: a current perspective , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  J. Bluestone,et al.  Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation , 1990, European journal of immunology.

[56]  R. Locksley,et al.  Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism , 1990, The Journal of experimental medicine.